APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Once lung function is lost to IPF, it is lost forever
Document ID: PC-MY-101489
07/01/2022
Author: Boehringer Ingelheim
Untreated IPF has devastating consequences. Treatment with anti-fibrotic therapy can slow lung function decline and delay IPF progression [1]
References:
1. Maher T and Strek ME. Respir Res. 2019;20(1):205.
RELATED CONTENT
PC-MY-101489
Production date: January 2022
Production date: January 2022